Program
Docetaxel
Also written as “docetaxel”, “Taxotere” and “HB1801”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms · Stomach Neoplasms · Lung Neoplasms, led by 27 companies.
Drug pageDocetaxel: every studyMany companies study it; this page follows only the 142 they lead. All 1,164 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 540 open or running | phase 4since Jan 18, 2006 | Nov 1, 1999 | none ahead |
| Hoffmann-La Rocheits history only | 220 open or running | phase 4since Aug 5, 2005 | Feb 12, 2004 | none ahead |
| CSPC Pharmaceutical Group | 1511 open or running | phase 3since Apr 20, 2023 | Mar 10, 2021 | Dec 16, 2026phase 3 · NCT06747338 |
| Eli Lillyits history only | 81 open or running | phase 3since Nov 1, 2004 | Nov 1, 2004 | May 2027phase 2 · NCT05999994 |
| Pfizerits history only | 70 open or running | phase 2since Jan 4, 2002 | Jan 4, 2002 | none ahead |
| GlaxoSmithKlineits history only | 60 open or running | phase 2since Jul 17, 2003 | Jul 17, 2003 | none ahead |
| Amgenits history only | 40 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Merckits history only | 30 open or running | phase 2since Oct 4, 2007 | Oct 4, 2007 | none ahead |
| Novaceaits history only | 30 open or running | phase 3since Aug 9, 2002 | Aug 9, 2002 | none ahead |
| Novartisits history only | 20 open or running | phase 3since Jun 29, 2004 | Jun 29, 2004 | none ahead |
| Samyang Biopharmaceuticalsits history only | 20 open or running | phase 1since Mar 21, 2011 | Mar 21, 2011 | none ahead |
| Academy Military Medical Science, Chinaits history only | 10 open or running | phase 2since Jul 14, 2008 | Jul 14, 2008 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 1since Nov 23, 2009 | Nov 23, 2009 | none ahead |
| HealthCare Global Enterpriseits history only | 10 open or running | phase 2since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| Hope Cancer Instituteits history only | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Ionis Pharmaceuticalsits history only | 10 open or running | phase 2since Nov 2, 2010 | Nov 2, 2010 | none ahead |
| Lidds ABits history only | 10 open or running | phase 1since Mar 18, 2021 | Mar 18, 2021 | none ahead |
| NanOlogyits history only | 10 open or running | phase 1since Feb 5, 2020 | Feb 5, 2020 | none ahead |
| Oshadi Drug Administrationits history only | 10 open or running | phase 2since May 7, 2014 | May 7, 2014 | none ahead |
| Relmada Therapeuticsits history only | 11 open or running | phase 2since Aug 8, 2024 | Aug 8, 2024 | Nov 2027phase 2 · NCT06663137 |
| Sarah Cannon Research Instituteits history only | 10 open or running | phase 2since Jun 27, 2007 | Jun 27, 2007 | none ahead |
| Shanghai Miracogenits history only | 11 open or running | phase 3since Feb 22, 2023 | Feb 22, 2023 | none ahead |
| Simcere Pharmaceutical Groupits history only | 10 open or running | phase 1since May 25, 2020 | May 25, 2020 | none ahead |
| Sumitomo Pharmaits history only | 10 open or running | phase 1since Dec 7, 2020 | Dec 7, 2020 | none ahead |
| Swedish Orphan Biovitrumits history only | 10 open or running | phase 3since Feb 5, 2003 | Feb 5, 2003 | none ahead |
| Zhuhai Beihai Biotechits history only | 11 open or running | phase 2since Dec 9, 2024 | Dec 9, 2024 | none ahead |
| Zivenaits history only | 10 open or running | phase 2since May 11, 2004 | May 11, 2004 | none ahead |
Also a collaborator on its studies: Jazz Pharmaceuticals Ireland, Parexel, Baili-Bio (Chengdu) Pharmaceutical, Clovis Oncology, Astellas Pharma, Exelixis, Gilead Sciences, iTeos Belgium, Intas Pharmaceuticals, Lambda Therapeutic Research, Medigen Biotechnology, US Biotest, Quintiles, MDS Pharma Services, AstraZeneca and Regeneron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of CSPC Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 10, 2021First study: phase 1 study in Advanced Solid TumorsFirst studyNCT04811118 · 27 enrolled · China
- Aug 19, 2021Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT05027204 · 94 enrolled · China
- Mar 24, 2022Phase 2 study in Platinum-resistant Recurrent Ovarian CancerNCT05325229 · 94 enrolled · China
- Nov 7, 20222 phase 2 studiesNCT05616494, NCT05705635
- Apr 20, 2023Phase 3 study in Breast NeoplasmsNCT05838066 · 880 planned · China
- May 8, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05863325 · 80 planned · China
- Feb 28, 2024Phase 3 study in Stomach NeoplasmsNCT06296706 · 630 planned · China
- Mar 13, 2024Phase 3 study in Squamous Cell Non-small Cell Lung CancerNCT06319313 · 534 planned
- Jun 24, 2024Phase 3 study in Advanced Pancreatic CancerNCT06492941 · 142 planned
- Dec 13, 2024Phase 3 study in Early or Locally Advanced HER2-positive Breast CancerNCT06747338 · 520 enrolled · China
- Jul 15, 2025Phase 2 study in Advanced Breast CancerNCT07083505 · 60 planned
- Aug 7, 2025Phase 2 study in HER2-positive Breast CancerNCT07116824 · 80 planned
- Feb 12, 2026Phase 3 study in Resectable HER2-positive Breast CancerNCT07441460 · 1,800 planned · China
- Aug 28, 2026Phase 3 study in HER2-Negative Advanced Breast CancerNCT07805135 · 430 planned
Ahead
- Dec 16, 2026Primary completion: phase 3 study in Early or Locally Advanced HER2-positive Breast CancerNCT06747338
- Jun 1, 2028Primary completion: phase 3 study in HER2-Negative Advanced Breast CancerNCT07805135
- Aug 7, 2034Primary completion: phase 3 study in Resectable HER2-positive Breast CancerNCT07441460
TargetBeta
“Tubulin inhibitor; Tubulin stabiliser”ChEMBL 37, by rule
Other programs on the same 15 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Paclitaxelrule | Hoffmann-La Roche | phase 4 | 202 |
| cabazitaxelrule | Sanofi | phase 4 | 21 |
| Vinblastinerule | Takeda | phase 4 | 4 |
| desoxyepothilone Brule | beijing-biostar-pharmaceuticals-co-ltd | phase 3 | 19 |
| plinabulinrule | beyondspring-pharmaceuticals-inc | phase 3 | 8 |
Studies
All 15 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07805135HER2-Negative Advanced Breast Cancer | 3 | Not yet recruiting | Jun 1, 2028 | 430 |
| NCT07441460Resectable HER2-positive Breast Cancer · China | 3 | Recruiting | Aug 7, 2034 | 1,800 |
| NCT07116824HER2-positive Breast Cancer | 2 | Not yet recruiting | Jul 15, 2026 | 80 |
| NCT07083505Advanced Breast Cancer | 2 | Not yet recruiting | Oct 11, 2026 | 60 |
| NCT06747338Early or Locally Advanced HER2-positive Breast Cancer · China | 3 | Active, not recruiting | Dec 16, 2026 | 520 |
| NCT06492941Advanced Pancreatic Cancer | 3 | Not yet recruiting | Apr 14, 2026 | 142 |
| NCT06319313Squamous Cell Non-small Cell Lung Cancer | 3 | Not yet recruiting | Jul 1, 2026 | 534 |
| NCT06296706Stomach Neoplasms · China | 3 | Recruiting | Jun 1, 2026 | 630 |
| NCT05863325Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Mar 2024 | 80 |
| NCT05838066Breast Neoplasms · China | 3 | Recruiting | Jul 31, 2025 | 880 |
| NCT05705635Gastric Adenocarcinoma · China | 2 | UNKNOWN | May 2023 | 100 |
| NCT05616494Pancreatic Neoplasms · China | 2 | Recruiting | Dec 31, 2024 | 53 |
| NCT05325229Platinum-resistant Recurrent Ovarian Cancer · China | 2 | UNKNOWN | Dec 2024 | 94 |
| NCT05027204Squamous Cell Carcinoma of Head and Neck · China | 2 | UNKNOWN | Oct 31, 2023 | 94 |
| NCT04811118Advanced Solid Tumors · China | 1 | UNKNOWN | Oct 31, 2022 | 27 |
How it is read
Names in the registry
- “Docetaxel”, 93 entries
- “docetaxel”, 37 entries
- “Taxotere”, 9 entries
- “HB1801”, 8 entries
- “Docetaxel for injection (Albumin-bound)”, 4 entries
Codes read as this program: CKD810.
Conditions, from the studies’ own filings
- Breast Neoplasms, 54 studies
- Carcinoma, Non-Small-Cell Lung, 48 studies
- Prostatic Neoplasms, 21 studies
- Stomach Neoplasms, 9 studies
- Lung Neoplasms, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.